2022
DOI: 10.3390/ijms23137068
|View full text |Cite
|
Sign up to set email alerts
|

Immunotherapy in NSCLC Patients with Brain Metastases

Abstract: Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcome… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
16
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 78 publications
0
16
0
Order By: Relevance
“…As a surrogate outcome for OS, PFS is now the most common end point used in clinical trials for patients with metastatic malignant neoplasms . Meanwhile, intracranial PFS is increasingly used as a primary end point among oncologic trials of systemic agents with favorable intracranial response rates . In this study, PFS had a high correlation with OS across all primary tumor subgroups.…”
Section: Discussionmentioning
confidence: 69%
See 1 more Smart Citation
“…As a surrogate outcome for OS, PFS is now the most common end point used in clinical trials for patients with metastatic malignant neoplasms . Meanwhile, intracranial PFS is increasingly used as a primary end point among oncologic trials of systemic agents with favorable intracranial response rates . In this study, PFS had a high correlation with OS across all primary tumor subgroups.…”
Section: Discussionmentioning
confidence: 69%
“… 15 Meanwhile, intracranial PFS is increasingly used as a primary end point among oncologic trials of systemic agents with favorable intracranial response rates. 29 , 30 In this study, PFS had a high correlation with OS across all primary tumor subgroups. Both intracranial and extracranial PFS demonstrated higher OS correlation than PFS; however, whether intracranial or extracranial PFS had the highest correlation with OS appeared to differ across primary tumor origin.…”
Section: Discussionmentioning
confidence: 99%
“…A subsequent study discovered that silencing KIF3A inhibited HepG2 LC cell proliferation. Stroma cells in the tumor microenvironment (TME), particularly immune cells, exert a vital function in modulating cancer cell malignant behavior [27][28][29]. They have been argued to be signi cant for predicting prognosis and treating cancer cases [30,31].…”
Section: Discussionmentioning
confidence: 99%
“…The major neurologic complication was brain radionecrosis, which occurred in 9.7% of the population and was significantly associated with tumour volume. 94,95 The management of radiation necrosis in ICI-treated patients constitutes another challenging issue because of the high doses of steroids that are required in this case. Bevacizumab administration and surgery may lessen the impact of steroids on both the IC and EC efficacy of ICI in carefully selected patients.…”
Section: Immunotherapy In Combination With Rtmentioning
confidence: 99%
“…Particularly, this combination led to 6.8% grade ≥ 3 toxicity including IC hypertension in 5.1%. The major neurologic complication was brain radionecrosis, which occurred in 9.7% of the population and was significantly associated with tumour volume 94,95 . The management of radiation necrosis in ICI‐treated patients constitutes another challenging issue because of the high doses of steroids that are required in this case.…”
Section: Immunotherapy In Combination With Rtmentioning
confidence: 99%